Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 7/20 | 0.53 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | TIPARP | Q7Z3E1 | 2/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.32 |
| ▸ | COMT | P21964 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14718548 | 0.87 | DAO (0.47) | DAOTIPARPDHODHMPOGPR84 | |
| Luvadaxistat SCHEMBL14719667 | 0.83 | DAO (0.48) | DAODHODHGPR84COMT | |
| SCHEMBL16234235 | 0.82 | DAO (0.41) | DAOTIPARPDHODH | |
| SCHEMBL30107675 | 0.82 | DAO (0.51) | DAODHODH | |
| SCHEMBL14718895 | 0.82 | DAO (0.51) | DAODHODH | |
| SCHEMBL16231716 | 0.81 | NOS1 (0.41) | DAOTIPARPDHODH | |
| SCHEMBL30107626 | 0.78 | DAO (0.56) | DAOTIPARPGPR84COMT | |
| SCHEMBL14718871 | 0.78 | DAO (0.56) | DAOTIPARPGPR84COMT | |
| SCHEMBL14719689 | 0.77 | DAO (0.49) | DAOTIPARPDHODHMPO | |
| SCHEMBL14719204 | 0.76 | DAO (0.49) | DAOTIPARPDHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10463663-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-11-05 | — | — | US | claimed |
| US-20180177780-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-28 | — | — | US | claimed |
| EP-3113778-B1 | PYRIDAZINE DERIVATIVES FOR USE IN THE PREVENTION OR TREATMENT OF AN ATAXIC DISORDER | TAKEDA PHARMACEUTICALS CO (JP) | 2018-06-06 | — | — | EP | claimed |
| US-9931340-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-04-03 | — | — | US | claimed |
| EP-2748149-B9 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-11-15 | — | — | EP | claimed |
| US-20170173007-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-06-22 | — | — | US | claimed |
| US-20170014407-A1 | PYRIDAZINE DERIVATIVES FOR USE IN THE PREVENTON OR TREATMENT OF AN ATAXIC DISORDER | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-19 | — | — | US | claimed |
| EP-3113778-A1 | PYRIDAZINE DERIVATIVES FOR USE IN THE PREVENTION OR TREATMENT OF AN ATAXIC DISORDER | Takeda Pharmaceutical Company Limited (JP) | 2017-01-11 | — | — | EP | claimed |
| US-9290456-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-03-22 | — | — | US | claimed |
| EP-2748149-B1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2015-10-21 | — | — | EP | claimed |
| WO-2015132608-A1 | PYRIDAZINE DERIVATIVES FOR USE IN THE PREVENTION OR TREATMENT OF AN ATAXIC DISORDER | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-11 | — | — | WO | claimed |
| US-20150030704-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-29 | — | — | US | claimed |
| EP-2748149-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2014-07-02 | — | — | EP | claimed |
| WO-2013027000-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | WO | claimed |
| US-20130052281-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | US | claimed |
| US-12186313-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-01-07 | — | — | US | disclosed |
| US-20230149396-A1 | ORAL SOLID PREPARATIONS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-18 | — | — | US | disclosed |
| WO-2013027000-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | WO | disclosed |
| WO-2013027000-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | WO | disclosed |
| US-20130052281-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130052281-A1 | NOVEL COMPOUNDS | ABCG2, F12, UGT1A1 | DAO 4565/4885PRMT5 1063/4885WDR77 1885/4885 |
| US-20150030704-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | PNPO, DAO, DPYD | DAO 2/4885PRMT5 991/4885WDR77 1862/4885 |
| US-20170014407-A1 | PYRIDAZINE DERIVATIVES FOR USE IN THE PREVENTON OR TREATMENT OF AN ATAXIC DISORDER | ATXN2, CLN6, ATXN10 | DAO 1144/4885PRMT5 358/4885WDR77 1565/4885 |
| US-12186313-B2 | Pyridazinone compounds and their use as DAAO inhibitors | PNPO, DAO, DPYD | DAO 2/4885PRMT5 991/4885WDR77 1862/4885 |
| US-20180177780-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | PNPO, DAO, DPYD | DAO 2/4885PRMT5 991/4885WDR77 1862/4885 |
| US-10463663-B2 | Pyridazinone compounds and their use as DAAO inhibitors | PNPO, DAO, DPYD | DAO 2/4885PRMT5 991/4885WDR77 1862/4885 |
| US-20230149396-A1 | ORAL SOLID PREPARATIONS | DAO, DDO, XDH | DAO 1/4885PRMT5 614/4885WDR77 755/4885 |
| US-20170173007-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | PNPO, DAO, DPYD | DAO 2/4885PRMT5 991/4885WDR77 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.